{ "company": "Thermo Fisher Scientific", "ticker": "TMO", "period": { "from": "2026-02-27", "to": "2026-03-29", "days": 30 }, "sentiment_breakdown": { "positive": 48, "negative": 24, "neutral": 49 }, "synthesis": { "executive_summary": "**Executive Summary: Thermo Fisher Scientific (TMO) Sentiment Analysis**\n\nSentiment analysis for Thermo Fisher Scientific (TMO) from February 27 to March 29, 2026, reveals a predominantly neutral to positive outlook. Of 121 analyzed items, 40.5% were neutral, 39.7% positive, and 19.8% negative, indicating a net positive sentiment. Key drivers of positive sentiment include the early completion of the Clario acquisition, which is projected to significantly boost TMO's 2026 revenue by approximately $1 billion and enhance adjusted EPS, strengthening its AI-driven competitive position in life sciences. Further positive momentum stemmed from strong quarterly earnings, exceeding analyst estimates, a 7.2% year-over-year revenue increase, and a raised quarterly dividend. Institutional confidence was also evident with Daymark Wealth Partners LLC substantially increasing its stake in TMO.\n\nConversely, negative sentiment drivers were less directly tied to TMO's operational or financial performance. The majority of top negative items originated from medical research publications discussing various diseases and health burdens (e.g., cancer cachexia, severe influenza, non-small cell lung cancer), which, while relevant to the broader healthcare sector, do not directly critique TMO. One additional negative item discussed a different small-cap cancer diagnostics company, not TMO. This suggests that the identified negative sentiment largely reflects general industry challenges or unrelated market discussions rather than specific adverse developments for Thermo Fisher Scientific.", "key_findings": [ "✓ Thermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating", "✓ Contextual High-Throughput 3D Volume Electron Microscopy Data Acquisition Using Artificial Intelligence.", "✓ Daymark Wealth Partners LLC Buys 7,003 Shares of Thermo Fisher Scientific Inc. $TMO", "✗ Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "✗ Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "✗ Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review." ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "Thermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.735 }, { "title": "Contextual High-Throughput 3D Volume Electron Microscopy Data Acquisition Using Artificial Intelligence.", "date": "2026 Mar 3", "source": "pubmed", "score": 0.677 }, { "title": "Daymark Wealth Partners LLC Buys 7,003 Shares of Thermo Fisher Scientific Inc. $TMO", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.66 }, { "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.637 }, { "title": "Is Thermo Fisher Scientific (TMO) One of the Best Conservative Stocks to Buy Right Now?", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.637 }, { "title": "Is Thermo Fisher Scientific (TMO) one of the best conservative stocks to buy right now?", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.637 }, { "title": "Agilent Technologies Inc. stock climbs on launch of advanced chromatography solutions boosting life sciences research", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.625 }, { "title": "ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.54 }, { "title": "Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.511 }, { "title": "Influence of computed tomography reconstruction algorithms on coronary artery calcium scores and reader agreement.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.494 } ], "top_negative": [ { "title": "Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "date": "2026-03-29", "source": "pubmed", "score": -0.743 }, { "title": "Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.67 }, { "title": "Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review.", "date": "2026 Feb 2", "source": "pubmed", "score": -0.66 }, { "title": "Late-night stock scanning led me to this tiny cancer diagnostics company", "date": "2026-03-06", "source": "reddit", "score": -0.66 }, { "title": "Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.612 }, { "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom", "date": "2026-03-26", "source": "alpha_vantage", "score": -0.477 }, { "title": "Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.421 }, { "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test", "date": "2026-03-25", "source": "alpha_vantage", "score": -0.402 }, { "title": "Diagnostic performance of somatostatin receptor positron emission tomography in preoperative evaluation of pancreatic neuroendocrine tumor lymph node metastases.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.382 }, { "title": "Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector", "date": "2026-03-25", "source": "alpha_vantage", "score": -0.34 } ], "raw_data": { "total_items": 121, "items": [ { "source": "alpha_vantage", "title": "Assenagon Asset Management S.A. Has $6.22 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-has-622-million-stock-holdings-in-thermo-fisher-scientific-inc-tmo-2026-03-29/", "date": "2026-03-29", "summary": "Assenagon Asset Management S.A. significantly reduced its stake in Thermo Fisher Scientific Inc. by 98.3% in Q4, now holding 10,740 shares valued at $6.223 million. Despite this, analysts maintain a \"Moderate Buy\" consensus with an average price target of $632.50. The article also notes recent insider selling by the CEO and EVP, alongside the company's recent dividend increase.", "sentiment_score": 0.233348, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Generate Investment Management Ltd Has $20.66 Million Stake in Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-generate-investment-management-ltd-has-2066-million-stake-in-thermo-fisher-scientific-inc-tmo-2026-03-28/", "date": "2026-03-28", "summary": "Generate Investment Management Ltd significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 131.4% in the fourth quarter of 2025, now holding 35,646 shares valued at $20.655 million. This comes as Thermo Fisher Scientific reported strong Q4 earnings, beating expectations, and raised its quarterly dividend, while analysts maintain a \"Moderate Buy\" rating with an average target price of $632.50. Despite institutional backing at 89.23%, some insider selling by executives has", "sentiment_score": 0.302127, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is It Time To Revisit Bio-Techne (TECH) After Recent Share Price Weakness?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/is-it-time-to-revisit-bio-techne-tech-after-recent-share-pri", "date": "2026-03-28", "summary": "Bio-Techne (TECH) has experienced significant share price weakness, with declines over the past week, month, and year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 29.1%. However, its current P/E ratio of 98.34x is considerably higher than the industry average and Simply Wall St's Fair Ratio, indicating it is overvalued on that metric.", "sentiment_score": 0.142866, "sentiment_label": "Neutral", "relevance_score": 0.624873, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Shares Sold by DAVENPORT & Co LLC", "url": "https://nationaltoday.com/us/ny/new-york/news/2026/03/28/thermo-fisher-scientific-shares-sold-by-davenport-co-llc/", "date": "2026-03-28", "summary": "DAVENPORT & Co LLC significantly reduced its stake in Thermo Fisher Scientific Inc. by 87.3% during the fourth quarter, selling 34,817 shares. The investment management firm now holds 5,070 shares valued at $2.94 million. This move reflects broader market trends and investor sentiment, though the institutional investor retains a holding, indicating continued long-term confidence.", "sentiment_score": -0.287921, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.97187, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Eagle Rock Investment Company LLC Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-eagle-rock-investment-company-llc-boosts-stock-position-in-thermo-fisher-scientific-inc-tmo-2026-03-28/", "date": "2026-03-28", "summary": "Eagle Rock Investment Company LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.9% in the fourth quarter, making the stock its 16th largest position. Other institutional investors also adjusted their holdings, while company insiders made notable stock sales. Analysts generally maintain a \"Moderate Buy\" rating for Thermo Fisher Scientific, which recently increased its quarterly dividend.", "sentiment_score": 0.394776, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Rating of \"Moderate Buy\" from Analysts", "url": "https://www.marketbeat.com/instant-alerts/thermo-fisher-scientific-inc-nysetmo-receives-consensus-rating-of-moderate-buy-from-analysts-2026-03-28/", "date": "2026-03-28", "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) has received a \"Moderate Buy\" consensus rating from twenty-two research firms, with most analysts issuing buy recommendations and an average 12-month target price of $632.50. The company recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. Insider activity shows some selling by executives, while institutional investors have significantly increased their positions in the company.", "sentiment_score": 0.492743, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-steady-position-in-molecular-diagnostics-amid-sector/69007382", "date": "2026-03-27", "summary": "Qiagen N.V. (QGEN) maintains a stable position in the molecular diagnostics and life sciences sector, providing essential sample and assay technologies for various applications. The company's diversified business model, global footprint, and focus on high-growth areas like next-generation sequencing and human identification make it an attractive consideration for North American investors seeking exposure to the biotech tools space. While facing competition and regulatory risks, Qiagen's consiste", "sentiment_score": 0.331728, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.628373, "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Inc Stock (TMO) Moved Down by 3.31% on Mar 27: What Investors Need To Know", "url": "https://www.tradingkey.com/news/Market-Movers/261729372-market-movers-tmo-20260327", "date": "2026-03-27", "summary": "Thermo Fisher Scientific (TMO) stock dropped 3.31% due to several factors, including margin pressures, cautious 2026 guidance, and integration risks from its recent acquisition of Clario Holdings. The decline was also influenced by broader market sentiment, insider sales, and an institutional adjustment by Vanguard. Despite these pressures, analysts largely maintain a \"Moderate Buy\" rating for the stock.", "sentiment_score": -0.404517, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Vanguard Amends 13G: Reports 0 Shares in Thermo Fisher (TMO)", "url": "https://www.stocktitan.net/sec-filings/TMO/schedule-13g-a-thermo-fisher-scientific-inc-amended-passive-investmen-f56247a52561.html", "date": "2026-03-27", "summary": "Vanguard Group has filed an amendment to its Schedule 13G/A, reporting 0 shares and 0% beneficial ownership in Thermo Fisher Scientific Inc. This change follows an internal realignment effective January 12, 2026, which disaggregated reporting responsibilities among Vanguard's subsidiaries and business divisions. The amendment clarifies that while Vanguard Group itself no longer directly reports ownership, its disaggregated entities continue to pursue similar investment strategies.", "sentiment_score": 0.006072, "sentiment_label": "Neutral", "relevance_score": 0.324414, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SHC/pressreleases/999492/q4-rundown-sotera-health-company-nasdaqshc-vs-other-research-tools-consumables-stocks/", "date": "2026-03-27", "summary": "This article provides a Q4 rundown of Sotera Health Company (NASDAQ:SHC) and other research tools & consumables stocks, highlighting their financial performance and market reception. Sotera Health exceeded analysts' expectations with strong revenues and a positive outlook, despite a subsequent stock dip. The article also reviews top performers like Bio-Techne and notes the weakest, Mettler-Toledo, while touching on broader market shifts driven by AI and geopolitical events.", "sentiment_score": 0.246752, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.742829, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "There's A Lot To Like About Agilent Technologies' (NYSE:A) Upcoming US$0.255 Dividend", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/theres-a-lot-to-like-about-agilent-technologies-nysea-upcomi", "date": "2026-03-27", "summary": "Agilent Technologies (NYSE:A) is set to pay a US$0.255 dividend, offering a trailing yield of 0.9%. The company demonstrates strong dividend sustainability with a low payout ratio of 22% of income and 28% of free cash flow, alongside robust earnings per share growth of 14% annually over the last five years. These factors, combined with a decade of consistent dividend growth, suggest an attractive investment for dividend-focused shareholders.", "sentiment_score": 0.021806, "sentiment_label": "Neutral", "relevance_score": 0.613127, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock: Precision instruments leader navigating life sciences and diagnosti", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-precision-instruments-leader-navigating/69004318", "date": "2026-03-27", "summary": "Agilent Technologies Inc. is a leader in precision instrumentation for life sciences, diagnostics, and applied chemical markets, providing critical tools for pharmaceuticals, biotech, and environmental testing. The company's business model is diversified across three primary segments, focusing on innovation, global expansion, and a strong competitive moat. It offers North American investors exposure to high-growth areas within healthcare, balanced by recurring revenues and a commitment to capita", "sentiment_score": 0.125479, "sentiment_label": "Neutral", "relevance_score": 0.723761, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "What You Need to Know Ahead of Thermo Fisher Scientific's Earnings Release", "url": "https://www.barchart.com/story/news/1000546/what-you-need-to-know-ahead-of-thermo-fisher-scientific-s-earnings-release", "date": "2026-03-27", "summary": "Thermo Fisher Scientific Inc. (TMO) is set to release its fiscal first-quarter earnings for 2026, with analysts expecting a 3.1% increase in EPS to $5.31. Despite consistently beating EPS estimates, TMO's stock has underperformed the S&P 500 over the past year. Analysts hold a \"Strong Buy\" rating for TMO, with a significant potential upside of 36.1% from current levels.", "sentiment_score": 0.410864, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Waters Corp Stock: Analytical Instruments Leader Faces Growth Challenges Amid Sector Tailwinds", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/waters-corp-stock-analytical-instruments-leader-faces-growth-challenges/69003163", "date": "2026-03-27", "summary": "Waters Corp (NYSE:WAT), a leader in analytical workflow solutions, faces growth challenges despite tailwinds in the scientific instruments sector. The company specializes in liquid chromatography and mass spectrometry, serving pharmaceutical, biotech, and environmental testing markets. While institutional investors like Vanguard maintain positions, recent performance has been mixed, with modest share declines and analyst ratings leaning towards a \"Moderate Buy.\"", "sentiment_score": 0.143055, "sentiment_label": "Neutral", "relevance_score": 0.600306, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Thermo Fisher and SHL Medical collaborate to deliver fully integrated drug-device solutions", "url": "https://www.biospectrumasia.com/news/27/27412/thermo-fisher-and-shl-medical-collaborate-to-deliver-fully-integrated-drug-device-solutions.html", "date": "2026-03-27", "summary": "Thermo Fisher Scientific has announced a strategic collaboration with SHL Medical and an expansion at its Ridgefield, NJ site to offer fully integrated drug-device solutions in the US. This initiative combines sterile manufacturing, device assembly, and commercial packaging, addressing the growing demand for patient-centric, self-administered injectable therapies. The partnership integrates SHL Medical's Molly® autoinjector platform with Thermo Fisher's capabilities, aiming to simplify developme", "sentiment_score": 0.404801, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.241, "confidence": 0.24 } }, { "source": "alpha_vantage", "title": "Whole Genome Sequencing Market Key Aspects, Benefits, and Challenges 2026-2033 | Major Companies - Illumina; Inc., QIAGEN, Agilent Technologies, PerkinElmer Genomics", "url": "https://www.openpr.com/news/4442890/whole-genome-sequencing-market-key-aspects-benefits", "date": "2026-03-27", "summary": "The global Whole Genome Sequencing (WGS) Market is projected to grow at a CAGR of 15% from 2024 to 2031, driven by rising demand for precision medicine, technological advancements, and decreasing costs. Key players include Illumina, Thermo Fisher Scientific, QIAGEN, and Agilent Technologies, with significant recent developments in the U.S. and Japan focusing on AI integration and expanded clinical adoption. The market covers instruments, consumables, and services across diagnostics, drug discove", "sentiment_score": 0.343982, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.627221, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Plus Therapeutics, Inc. Announces Appointment of Ron Andrews to Its Board of Directors", "url": "https://www.marketscreener.com/news/plus-therapeutics-inc-announces-appointment-of-ron-andrews-to-its-board-of-directors-ce7e51dbdf88ff23", "date": "2026-03-27", "summary": "Plus Therapeutics, Inc. has announced the appointment of Ron Andrews, a veteran in the diagnostics industry, to its Board of Directors. Andrews brings over 35 years of experience leading organizations in diagnostics and molecular diagnostics, including roles at Abbott Diagnostics, Roche Molecular Diagnostics, and several start-up companies. His expertise encompasses product development, fundraising, and significant capitalization events, making him a valuable addition to Plus Therapeutics' leade", "sentiment_score": 0.148358, "sentiment_label": "Neutral", "relevance_score": 0.646982, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is Thermo Fisher Scientific (TMO) One of the Best Conservative Stocks to Buy Right Now?", "url": "https://www.insidermonkey.com/blog/is-thermo-fisher-scientific-tmo-one-of-the-best-conservative-stocks-to-buy-right-now-1725414/?amp=1", "date": "2026-03-27", "summary": "Thermo Fisher Scientific (TMO) is highlighted as a conservative stock to consider after its acquisition of Clario Holdings, Inc., which is expected to contribute significantly to its biopharma services segment with attractive financial profiles and synergy realizations. The article mentions TMO's extensive product and service offerings in pharmaceuticals and biotechnology. It also includes a promotional section for an AI stock, suggesting it has greater upside potential than TMO.", "sentiment_score": 0.321046, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.978567, "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "alpha_vantage", "title": "Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Still a Buy?", "url": "https://www.marketbeat.com/instant-alerts/stoke-therapeutics-nasdaqstok-sees-unusually-high-trading-volume-still-a-buy-2026-03-26/", "date": "2026-03-26", "summary": "Stoke Therapeutics (NASDAQ:STOK) experienced an unusually high trading volume, with shares increasing 240% from the previous session. Despite notable insider selling, analysts maintain a \"Moderate Buy\" consensus with an average price target of $41.83, some as high as $60. The company, focused on genetic medicines for rare disorders, also saw significant institutional investment in the last quarter.", "sentiment_score": 0.31993, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.632891, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Thermo Fisher Scientific (TMO) After Recent Share Price Weakness?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-it-time-to-reassess-thermo-fisher-scientific-tmo-after-re", "date": "2026-03-26", "summary": "This article reassesses Thermo Fisher Scientific (TMO) following recent share price weakness. Using a Discounted Cash Flow analysis, the stock is estimated to be roughly 4.3% undervalued, while its P/E ratio suggests it is undervalued compared to industry and peer averages. The article encourages investors to use Simply Wall St's \"Narratives\" feature to align valuation with their personal investment outlook.", "sentiment_score": 0.272291, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy", "url": "https://www.timothysykes.com/news/enliven-therapeutics-inc-elvn-news-2026_03_26/", "date": "2026-03-26", "summary": "Enliven Therapeutics Inc. (ELVN) stock surged by 13.99% following promising developments and FDA designations for its ELVN-001 candidate. The market's positive reaction is further fueled by Merck's acquisition of Terns Pharmaceuticals, which validates the chronic myeloid leukemia market and highlights the potential of Enliven's drug. Despite a recent quarterly loss, Enliven maintains a strong cash position, and analysts like Mizuho have raised price targets, indicating confidence in its growth p", "sentiment_score": 0.315032, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.632412, "sentiment": { "label": "positive", "score": 0.54, "confidence": 0.54 } }, { "source": "alpha_vantage", "title": "Is Thermo Fisher Scientific (TMO) one of the best conservative stocks to buy right now?", "url": "https://www.msn.com/en-us/money/markets/is-thermo-fisher-scientific-tmo-one-of-the-best-conservative-stocks-to-buy-right-now/ar-AA1ZtssQ?ocid=finance-verthp-feeds", "date": "2026-03-26", "summary": "This article evaluates Thermo Fisher Scientific (TMO) as a potential conservative stock investment. It aims to determine if TMO's financial performance and market position make it an attractive option for investors seeking stability.", "sentiment_score": 0.332873, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "alpha_vantage", "title": "Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/qiagen-n-v-stock-a-core-player-in-molecular-diagnostics-for-long-term/68995799", "date": "2026-03-26", "summary": "Qiagen N.V. (ISIN: NL0012169213) is highlighted as a leading molecular diagnostics and life sciences tools company, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The article details its business model, core operations emphasizing recurring revenue from consumables, and strong market position in areas like next-generation sequencing and point-of-care testing. It also addresses the company's relevance for North American investors, competitive advantages, a", "sentiment_score": 0.225276, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.627987, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board", "url": "https://www.stocktitan.net/sec-filings/PSTV/8-k-plus-therapeutics-inc-reports-material-event-fb950f1b8d69.html", "date": "2026-03-26", "summary": "Plus Therapeutics (NASDAQ: PSTV) announced the appointment of Ronald A. Andrews to its board of directors, effective March 20, 2026. Andrews will fill the vacancy left by Dr. Robert Lenk's resignation and will also serve on the Nominating and Corporate Governance Committee, qualifying as an independent director under Nasdaq rules. He brings over 35 years of leadership experience in diagnostics and molecular diagnostics, including previous CEO roles and multiple board positions.", "sentiment_score": 0.11044, "sentiment_label": "Neutral", "relevance_score": 0.634054, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Veteran tied to $15B in exits joins Plus Therapeutics board", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-appoints-diagnostics-and-molecular-diagnostics-x9l3y8uq7ics.html", "date": "2026-03-26", "summary": "Plus Therapeutics (Nasdaq: PSTV) has appointed diagnostics industry veteran Ron Andrews to its Board of Directors. Andrews brings over 35 years of experience from companies like Abbott, Roche, and Thermo Fisher, and has been involved in over $600 million in capitalization and approximately $15 billion in exits. He will play a key role in scaling CNSide, a cerebrospinal-fluid diagnostic for leptomeningeal metastases, and advise on strategy, fundraising, and commercialization for the company's dia", "sentiment_score": 0.108713, "sentiment_label": "Neutral", "relevance_score": 0.649502, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock climbs on launch of advanced chromatography solutions boosting life sciences research", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-climbs-on-launch-of-advanced/68993869", "date": "2026-03-26", "summary": "Agilent Technologies Inc. (US00846U1016) stock has risen following the launch of new chromatography solutions designed to accelerate life sciences research and drug discovery. The company's innovations address key challenges in biotechnology R&D, positioning Agilent as a leader in analytical instrumentation and attracting investor interest. This development comes amid renewed investor appetite for life sciences enablers and aims to expand Agilent's market share in high-growth areas.", "sentiment_score": 0.26608, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.697313, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-sector-slowdown-as-q4/68989833", "date": "2026-03-26", "summary": "Revvity Inc. is facing pressure due to a slowdown in the life sciences sector, marked by reduced research funding and biopharma spending cuts, which led to flat Q4 revenue and organic declines. US investors should monitor the upcoming Q4 results for insights into NIH funding impacts, biopharma R&D recovery, and the integration of acquisitions like BioLegend, especially given the company's significant US customer base and the resilience of its diagnostics segment. Despite sector headwinds, the co", "sentiment_score": -0.116231, "sentiment_label": "Neutral", "relevance_score": 0.661273, "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock climbs amid new chromatography solutions launch signaling life sciences expansion", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-climbs-amid-new-chromatography-solutions/68989819", "date": "2026-03-26", "summary": "Agilent Technologies Inc. (NYSE: A) stock rose after the company launched new chromatography solutions, enhancing its offerings for the life sciences sector. These advanced tools, designed for complex biomolecule analysis, are expected to accelerate drug discovery and boost Agilent's market share in biopharma and diagnostics. The move aligns with growing demand for precise analytical instruments and is seen as a strategic push into high-growth markets, attracting investor confidence.", "sentiment_score": 0.105679, "sentiment_label": "Neutral", "relevance_score": 0.621328, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/illumina-inc-stock-navigates-grail-divestiture-challenges-amid-biotech/68989172", "date": "2026-03-26", "summary": "Illumina Inc. (ISIN: US4523271090) is facing market pressures due to the divestiture of its cancer detection subsidiary, Grail, and broader biotech sector challenges. The company's stock is impacted by regulatory scrutiny over the Grail acquisition, ongoing legal battles, and a softening biotech market with reduced funding and increased competition. Despite these headwinds, Illumina maintains a strong balance sheet and is focusing on core genomic sequencing platforms and pipeline innovations to ", "sentiment_score": 0.1113, "sentiment_label": "Neutral", "relevance_score": 0.605583, "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "List of 55 Acquisitions by Thermo Fisher Scientific (Mar 2026)", "url": "https://tracxn.com/d/acquisitions/acquisitions-by-thermo-fisher-scientific/__3TRGFxUu5eCJoMITE-e61ZEC_LKnhkY6JUsM7B5inds", "date": "2026-03-26", "summary": "This article details Thermo Fisher Scientific's 55 acquisitions, highlighting their most active years in 2017 and 2021 with five acquisitions each. The company's recent acquisition was Clario for $9 billion in November 2025, a CRO in the biopharma sector. Thermo Fisher Scientific primarily focuses on Life Sciences Platforms and Tools and Genomics sectors, with significant activity in the United States.", "sentiment_score": 0.337867, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock faces pressure amid life sciences slowdown and market shifts", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/danaher-corp-stock-faces-pressure-amid-life-sciences-slowdown-and-market/68988866", "date": "2026-03-26", "summary": "Danaher Corp. (ISIN: US2358511028) is experiencing stock pressure due to a slowdown in its life sciences division, a critical revenue component. The segment faces reduced demand post-pandemic and tighter biotech funding, prompting Danaher to strategically divest non-core assets and focus on higher-growth areas through its \"Danaher Business System.\" Despite these challenges, the company maintains robust free cash flow and a strong balance sheet, positioning it for potential recovery and opportuni", "sentiment_score": 0.140117, "sentiment_label": "Neutral", "relevance_score": 0.673801, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors", "url": "https://www.bitget.com/asia/news/detail/12560605306690", "date": "2026-03-26", "summary": "Plus Therapeutics, a healthcare company focused on CNS cancers, has appointed Ron Andrews, a diagnostics industry veteran, to its Board of Directors. Andrews brings over 35 years of experience in diagnostics and molecular diagnostics, with a strong background in scaling organizations and securing capital. His expertise is expected to significantly benefit the company, particularly in the global expansion of its CNSide diagnostic platform.", "sentiment_score": 0.239975, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.607974, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year", "url": "https://www.marketbeat.com/instant-alerts/nautilus-biotechnology-unveils-voyager-proteomics-platform-targets-beta-access-in-2h-and-launch-next-year-2026-03-25/", "date": "2026-03-25", "summary": "Nautilus Biotechnology (NASDAQ: NAUT) has revealed its new Voyager proteomics platform, which aims to provide high-resolution, single-molecule protein analysis to improve drug development and diagnostics. The benchtop instrument is expected to be priced around $1 million, with beta access targeted for the second half of the year and general availability in 2027. The company projects the proteomics market to reach $57 billion by 2030 and has sufficient cash runway through 2027 to support its laun", "sentiment_score": 0.10761, "sentiment_label": "Neutral", "relevance_score": 0.748505, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price-1", "date": "2026-03-25", "summary": "Danaher (DHR) shares have experienced a recent decline, prompting a reassessment of its valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 16.7% with an intrinsic value of $224.64 per share, its current P/E ratio of 36.76x is above the industry average, indicating it might be overvalued based on earnings comparisons. Investors can use Simply Wall St's \"Narratives\" feature to apply their own future forecasts to the company's valuation.", "sentiment_score": 0.100941, "sentiment_label": "Neutral", "relevance_score": 0.640615, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?", "url": "https://www.bitget.com/news/detail/12560605304566", "date": "2026-03-25", "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress", "sentiment_score": 0.015754, "sentiment_label": "Neutral", "relevance_score": 0.616238, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutio", "url": "https://www.pharmiweb.com/press-release/2026-03-25/thermo-fisher-scientific-and-shl-medical-collaborate-to-deliver-fully-integrated-drug-device-solutio", "date": "2026-03-25", "summary": "Thermo Fisher Scientific and SHL Medical have announced a strategic collaboration to provide fully integrated drug-device solutions. This partnership, combined with an expansion at Thermo Fisher's Ridgefield, NJ site, will offer sterile manufacturing, device assembly, and commercial packaging for drug-device combination products in a single U.S. location. The initiative aims to streamline supply chains and accelerate the delivery of self-administered injectable therapies to patients.", "sentiment_score": 0.007202, "sentiment_label": "Neutral", "relevance_score": 0.33383, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions", "url": "https://www.biospace.com/press-releases/thermo-fisher-scientific-and-shl-medical-collaborate-to-deliver-fully-integrated-drug-device-solutions", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has announced a strategic collaboration with SHL Medical and an expansion of its Ridgefield, NJ facility. This partnership aims to provide fully integrated drug-device solutions in the U.S., combining sterile fill-finish, device final assembly, and commercial packaging for drug-device combination products. The initiative seeks to streamline supply chains and accelerate the delivery of therapies, especially for self-administered injectable treatments.", "sentiment_score": 0.043733, "sentiment_label": "Neutral", "relevance_score": 0.315361, "sentiment": { "label": "positive", "score": 0.241, "confidence": 0.24 } }, { "source": "alpha_vantage", "title": "Thermo Fisher completes $8.9B buyout of Clario", "url": "https://www.medtechdive.com/news/thermo-fisher-completes-89b-buyout-of-clario/815638/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has finalized its $8.9 billion acquisition of Clario, enhancing its capabilities in clinical trial endpoint data management. By integrating Clario's data capture and interpretation technology with its existing biological sample analysis, Thermo Fisher aims to create a unified, high-growth solution for drug developers. The deal, which includes potential earn-out payments, received approval from the European Commission with minimal competition concerns and is part of Therm", "sentiment_score": 0.412524, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Registry", "url": "https://www.contractpharma.com/breaking-news/thermo-fisher-scientific-launches-ppd-corevitas-alzheimers-registry/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has launched the PPD CorEvitas Alzheimer’s Disease Registry, an international and multi-country initiative aimed at generating real-world data to evaluate drug safety and effectiveness. The registry, which has already enrolled its first patient, will provide a comprehensive understanding of Alzheimer's therapy outcomes, long-term safety, and treatment patterns from routine clinical practice. This effort will help inform regulators, clinicians, patients, and caregivers by", "sentiment_score": 0.402621, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/haemonetics-corp-stock-faces-uncertainty-amid-lack-of-fresh-catalysts-in/68984630", "date": "2026-03-25", "summary": "Haemonetics Corp stock is currently in a holding pattern due to a lack of fresh catalysts in the blood management sector, despite steady demand for its plasma collection and transfusion technologies. The company, a leader in automated blood processing, benefits from recurring disposable sales in its Plasma and Blood Center segments. Investors should consider the company's solid financial health and", "sentiment_score": 0.120727, "sentiment_label": "Neutral", "relevance_score": 0.617184, "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific acquires Clario for nearly $8.9bn", "url": "https://www.clinicaltrialsarena.com/news/thermo-fisher-scientific-acquires-clario/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has completed the acquisition of Clario, a provider of endpoint data solutions for clinical trials, for approximately $8.875 billion in cash. The deal includes additional payments based on Clario's future performance and is expected to contribute positively to Thermo Fisher's operating margin, with significant synergies projected over five years. Clario's platform has supported a large percentage of new drug approvals by the EMA and FDA, integrating trial endpoint data f", "sentiment_score": 0.489793, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Danaher (NYSE: DHR) 2026 proxy outlines governance, pay and $9.9B Masimo deal", "url": "https://www.stocktitan.net/sec-filings/DHR/def-14a-danaher-corp-de-definitive-proxy-statement-626e62bcbf87.html", "date": "2026-03-25", "summary": "Danaher's 2026 proxy statement details upcoming annual meeting proposals, including the election of directors, ratification of Ernst & Young LLP as auditor, an advisory vote on executive compensation, and approval of amendments to the Omnibus Incentive Plan. The company highlights strong 2025 financial performance with $24.6 billion in sales and outlines its agreement to acquire Masimo Corporation for $9.9 billion. The proxy also emphasizes Danaher's commitment to robust corporate governance pra", "sentiment_score": 0.160701, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.723387, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions", "url": "https://www.businesswire.com/news/home/20260325458608/en/Thermo-Fisher-Scientific-and-SHL-Medical-Collaborate-to-Deliver-Fully-Integrated-Drug-Device-Solutions", "date": "2026-03-25", "summary": "Thermo Fisher Scientific and SHL Medical have entered a strategic collaboration and expanded capacity at Thermo Fisher's Ridgefield, NJ site to offer fully integrated drug-device solutions in the U.S. This partnership will combine sterile fill-finish manufacturing with SHL Medical's Molly® autoinjector platform, device final assembly, and packaging. The initiative aims to simplify supply chains, accelerate timelines, and address the growing demand for patient-centric, self-administered injectabl", "sentiment_score": 0.029312, "sentiment_label": "Neutral", "relevance_score": 0.328832, "sentiment": { "label": "positive", "score": 0.241, "confidence": 0.24 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific completes Clario Holdings acquisition", "url": "https://medicalbuyer.co.in/thermo-fisher-scientific-completes-clario-holdings-acquisition/", "date": "2026-03-25", "summary": "Thermo Fisher Scientific has completed its acquisition of Clario Holdings Inc. for $8.875 billion in cash, with potential earnout payments. Clario's expertise in integrating clinical trial endpoint data will enhance Thermo Fisher's clinical research offerings, allowing for faster and more informed drug development. The acquisition is expected to contribute $0.45 to Thermo Fisher's adjusted EPS in the first year and achieve significant synergy realized over five years.", "sentiment_score": 0.484535, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Inc. $TMO Stake Decreased by Professional Advisory Services Inc.", "url": "https://www.marketbeat.com/instant-alerts/filing-thermo-fisher-scientific-inc-tmo-stake-decreased-by-professional-advisory-services-inc-2026-03-25/", "date": "2026-03-25", "summary": "Professional Advisory Services Inc. reduced its stake in Thermo Fisher Scientific Inc. by 14.3% in Q4 2025, selling 8,491 shares and now holding 51,020 shares valued at $29.56 million. Despite this, Thermo Fisher beat Q4 earnings and revenue estimates, and analysts have a \"Moderate Buy\" rating with an average target price of $633.68. The company also increased its quarterly dividend to $0.47, though recent insider activity shows sales by executives.", "sentiment_score": 0.184162, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "U.S. Compound Management Market Is Going to Boom | Thermo Fisher", "url": "https://www.openpr.com/news/4439576/u-s-compound-management-market-is-going-to-boom-thermo-fisher", "date": "2026-03-25", "summary": "Coherent Market Insights has published a report on the \"U.S. Compound Management Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033\". The report provides an in-depth analysis of market performance, competition, regional distribution, and growth potential, making it a valuable tool for entrepreneurs, investors, and business strategists. It also includes key market players, segmentation by end-user, research methodology, and strategic points of analysis.", "sentiment_score": 0.747737, "sentiment_label": "Bullish", "relevance_score": 0.948313, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating", "url": "https://www.tipranks.com/news/ratings/thermo-fisher-scientific-early-clario-close-enhances-2026-growth-outlook-and-ai-driven-competitive-position-supporting-buy-rating-ratings-news?utm_source=marketbeat.com&utm_medium=referral", "date": "2026-03-25", "summary": "Bank of America Securities analyst Michael Ryskin has reaffirmed a Buy rating for Thermo Fisher Scientific (TMO), citing the early completion of the Clario acquisition. This acquisition is expected to significantly boost Thermo Fisher's 2026 revenue by approximately $1 billion and enhance adjusted EPS, strengthening its competitive edge in AI-enabled life science tools and clinical research. Another report from TipRanks – PerPlexity also reiterated a Buy rating, highlighting the strategic integr", "sentiment_score": 0.839375, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Daymark Wealth Partners LLC Buys 7,003 Shares of Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-daymark-wealth-partners-llc-buys-7003-shares-of-thermo-fisher-scientific-inc-tmo-2026-03-25/", "date": "2026-03-25", "summary": "Daymark Wealth Partners LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 985% in the fourth quarter, acquiring an additional 7,003 shares, bringing its total to 7,714 shares valued at $4.47 million. This move comes as Thermo Fisher Scientific reported strong quarterly earnings, beating analyst estimates with EPS of $6.57 and a revenue increase of 7.2% year-over-year to $12.22 billion. The company also raised its quarterly dividend to $0.47 per share, annualize", "sentiment_score": 0.492334, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-sector-slowdown-and/68980506", "date": "2026-03-25", "summary": "Revvity Inc. is facing stock pressure due to a slowdown in the life sciences sector, with flat Q4 revenue and organic declines in research tools. Despite resilience in its diagnostics segment and strategic acquisitions like BioLegend, the company's performance is sensitive to federal funding cycles and biopharma R&D spending. US investors are monitoring its upcoming full-year 2026 guidance and the integration of new acquisitions, viewing it as a value opportunity given its current valuation and ", "sentiment_score": -0.116812, "sentiment_label": "Neutral", "relevance_score": 0.649153, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Inc. (TMO) announces the opening of cryo-electron microscopy drug discovery center in South San Francisco", "url": "https://www.msn.com/en-us/money/other/thermo-fisher-scientific-inc-tmo-announces-the-opening-of-cryo-electron-microscopy-drug-discovery-center-in-south-san-francisco/ar-AA1XTj30", "date": "2026-03-25", "summary": "Thermo Fisher Scientific Inc. (TMO) has announced the opening of a new cryo-electron microscopy (cryo-EM) drug discovery center in South San Francisco. This center aims to accelerate drug development by providing advanced cryo-EM technology for structural biology research. The facility will likely support pharmaceutical and biotechnology companies in their efforts to develop new treatments.", "sentiment_score": 0.33912, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-24", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774526000066/0000097745-26-000066-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41898871", "title": "Internal Validation of a Mitochondrial DNA Control Region Sequencing Workflow Using Precision ID mtDNA Whole Genome Panel, Ion Chef™ System and Ion S5™ XL System.", "authors": "Shue BH et al.", "journal": "Genes", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41898871/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41896400", "title": "Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "authors": "Meeraus W et al.", "journal": "Infectious diseases and therapy", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896400/", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41895568", "title": "Accumulation Patterns of Polychlorinated Alkanes in an Arctic Marine Food Web.", "authors": "Giebichenstein J et al.", "journal": "Environmental research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895568/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41887965", "title": "Influence of computed tomography reconstruction algorithms on coronary artery calcium scores and reader agreement.", "authors": "Yang LD et al.", "journal": "Journal of cardiovascular computed tomography", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41887965/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41887157", "title": "Corrigendum to \"Systemic distribution and transplacental transfer of micro- and nanoplastics in a filter-feeding marine predator\" [Environ. Res. Volume 298, 1 June 2026, 124237].", "authors": "Ruiz-Sagalés M et al.", "journal": "Environmental research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41887157/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41886673", "title": "Oral nutritional interventions in hospitalised older people at nutritional risk: a network meta-analysis of individual participant data.", "authors": "Kiesswetter E et al.", "journal": "The Cochrane database of systematic reviews", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41886673/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41884877", "title": "Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "authors": "Okamura M et al.", "journal": "Progress in rehabilitation medicine", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41884877/", "sentiment": { "label": "negative", "score": -0.743, "confidence": 0.74 } }, { "source": "pubmed", "pmid": "41883204", "title": "Delonix regia flower extract protects against diabetic cardiac remodeling via modulating eNOS/NO/cGMP and NF-κB/iNOS/TNF-α trajectories.", "authors": "Hassan N et al.", "journal": "The Journal of pharmacy and pharmacology", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41883204/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41882535", "title": "Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.", "authors": "Sartini C et al.", "journal": "BMC gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882535/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41882365", "title": "Electrochemical corrosion accompanies dendrite growth in solid electrolytes.", "authors": "Fincher CD et al.", "journal": "Nature", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882365/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41880124", "title": "Development of the Patient Satisfaction with Medication for Diabetes (PSMD) questionnaire.", "authors": "Boye KS et al.", "journal": "Journal of patient-reported outcomes", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41880124/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41879365", "title": "Giant Magnetostriction in Ferrimagnetic SmFe(5)As(3).", "authors": "Karychort O et al.", "journal": "Angewandte Chemie (International ed. in English)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41879365/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41878748", "title": "Characteristics of Adult Severe Uncontrolled Asthma Patients in Primary Care and Modifications in Prescribed Inhalation Treatments.", "authors": "Konradsen JR et al.", "journal": "Journal of asthma and allergy", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41878748/", "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "pubmed", "pmid": "41876063", "title": "Asthma Impairment and Risk Questionnaire predicts short- and long-term exacerbation occurrence across asthma severities.", "authors": "McCann WA et al.", "journal": "Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876063/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41875590", "title": "Multi-laboratory development of bioanalytical methods for two cyclic peptides, cyclorasin9A5 and 3003pep.", "authors": "Ishikawa R et al.", "journal": "Journal of chromatography. B, Analytical technologies in the biomedical and life sciences", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41875590/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41870027", "title": "Automated Online Direct mRNA Sequence Mapping Using Partial RNase T1 Digests.", "authors": "Dale JS et al.", "journal": "Analytical chemistry", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870027/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41870025", "title": "Molecular Probes for Sulfatase Detection and Bio-Imaging.", "authors": "Cheekatla SR et al.", "journal": "Chembiochem : a European journal of chemical biology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870025/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41865189", "title": "Low-resolution FAIMS for increased peptide coverage in low-load and single-cell proteomics.", "authors": "Hoch DG et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41865189/", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41864206", "title": "The E3-ome gene-centric compendium reveals the human E3 ligase landscape.", "authors": "Chua NK et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864206/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41859043", "title": "Clinically aggressive early-onset pancreatic ductal adenocarcinoma with KRAS wild-type status: A case report.", "authors": "Avendaño ME et al.", "journal": "Biomedical reports", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41859043/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41857718", "title": "-Impact of first-trimester preeclampsia screening on perinatal and maternal morbidity: the RANSPRE open multicenter randomized trial.", "authors": "Tsatsaris V et al.", "journal": "BMC pregnancy and childbirth", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41857718/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41857682", "title": "Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.", "authors": "Musallam KM et al.", "journal": "European journal of haematology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41857682/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41850747", "title": "Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.", "authors": "Fordham AM et al.", "journal": "Molecular cancer therapeutics", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41850747/", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41849846", "title": "Diagnostic performance of somatostatin receptor positron emission tomography in preoperative evaluation of pancreatic neuroendocrine tumor lymph node metastases.", "authors": "Gudmundsdottir H et al.", "journal": "Surgery", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41849846/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41847855", "title": "CD5L:p40, a novel heterodimeric regulator of type 2 inflammation.", "authors": "Wang C et al.", "journal": "Journal of immunology (Baltimore, Md. : 1950)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41847855/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41846680", "title": "Gestational age amplifies the risk of airflow obstruction in adult smokers with asthma.", "authors": "Konradsen JR et al.", "journal": "ERJ open research", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41846680/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41844540", "title": "Reducing Hospital Readmissions for Injection Drug Use-Related Infections: A Rapid Qualitative Analysis of Health Care Teams' Consultations to Inform Intervention Design.", "authors": "Key S et al.", "journal": "Journal of addiction medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41844540/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41843665", "title": "Nudibranch color diversity shares a common physical basis in guanine photonic structure 'pixels'.", "authors": "Humphrey S et al.", "journal": "Proceedings of the National Academy of Sciences of the United States of America", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41843665/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41843174", "title": "Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells.", "authors": "Luanpitpong S et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843174/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41843011", "title": "Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study.", "authors": "Kulthanan K et al.", "journal": "American journal of clinical dermatology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843011/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41827732", "title": "Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review.", "authors": "Delcuratolo MD et al.", "journal": "Cancers", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41827732/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41825348", "title": "High-sensitivity MAM to support early-stage activities during biotherapeutic development.", "authors": "Millán-Martín S et al.", "journal": "Journal of chromatography. A", "date": "2026 May 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825348/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41824798", "title": "Contextual High-Throughput 3D Volume Electron Microscopy Data Acquisition Using Artificial Intelligence.", "authors": "Hurník Konečná T et al.", "journal": "Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41824798/", "sentiment": { "label": "positive", "score": 0.677, "confidence": 0.68 } }, { "source": "pubmed", "pmid": "41820745", "title": "Podcast: Adherence to Injectables.", "authors": "Sánchez J", "journal": "Dermatology and therapy", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41820745/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41814618", "title": "Poppy seed anaphylaxis: clinical and allergic features.", "authors": "Novembre E et al.", "journal": "Allergologia et immunopathologia", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41814618/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41812769", "title": "Muscle movement and metabolism: exercise and skeletal muscle as mediators of health-a report from the 26th Annual Harvard Nutrition Obesity Symposium, 2025.", "authors": "Carollo L et al.", "journal": "The American journal of clinical nutrition", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41812769/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41812750", "title": "Systemic distribution and transplacental transfer of micro- and nanoplastics in a filter-feeding marine predator.", "authors": "Ruiz-Sagalés M et al.", "journal": "Environmental research", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41812750/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41811753", "title": "EIQuan: A Stacked Ensemble Learning-Based Predictor for Quantification of Nontargeted Chemicals in Gas Chromatography Coupled with Electron Ionization High-Resolution Mass Spectrometry Analysis.", "authors": "Liu Y et al.", "journal": "Environmental science & technology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41811753/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806905", "title": "Pathology in motion: Automation from specimen to report.", "authors": "L'Imperio V et al.", "journal": "Critical reviews in oncology/hematology", "date": "2026 Mar 8", "url": "https://pubmed.ncbi.nlm.nih.gov/41806905/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806102", "title": "Identification of intranasal oxytocin plasma proteome signatures.", "authors": "Breithaupt L et al.", "journal": "Endocrine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41806102/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41801661", "title": "Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data.", "authors": "Ashaye A et al.", "journal": "Therapeutic innovation & regulatory science", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41801661/", "sentiment": { "label": "positive", "score": 0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41798765", "title": "Non-syndromic hyper-IgE in children: A practical approach.", "authors": "Castagnoli R et al.", "journal": "The World Allergy Organization journal", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41798765/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41794910", "title": "A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed Study.", "authors": "Kwatra SG et al.", "journal": "Dermatology and therapy", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41794910/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41793578", "title": "Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.", "authors": "Shinde S et al.", "journal": "The patient", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41793578/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41793572", "title": "A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.", "authors": "Zinzani PL et al.", "journal": "Oncology and therapy", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41793572/", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41792598", "title": "Diagnostic accuracy of chip hybridization from formalin-fixed paraffin embedded bioptic specimens in a cohort with predominantly extrapulmonary mycobacterial disease.", "authors": "Winkelmann R et al.", "journal": "BMC microbiology", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41792598/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41792463", "title": "Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma.", "authors": "Richardson SA et al.", "journal": "EMBO molecular medicine", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41792463/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41792053", "title": "Insights into Api m 10-Isoforms and Splice Variants: More Than One Major IgE-Binding Epitope.", "authors": "Paulus-Tremel KE et al.", "journal": "Clinical and translational allergy", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41792053/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41786905", "title": "Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.", "authors": "Hunt AL et al.", "journal": "NPJ precision oncology", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41786905/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "edgar_news", "title": "Thermo Fisher Scientific Inc.", "text": "Thermo Fisher Scientific completed the acquisition of Clario Holdings for $8.875B, enhancing its position as a partner for pharma and biotech clients. Clario's solutions will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment. The acquisition is expected to contribute $0.45 of adjusted earnings per share in the first year.\n\n*Thermo Fisher Scientific Inc. [TMO](https://www.google.com/finance/quote/TMO:NYSE) is headquartered in Waltham, MA.*\n\n[Source](https://www.sec", "author": "edgar_news_01", "score": 1, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/edgar_news/comments/1s2chdn/thermo_fisher_scientific_inc/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BioTechHealthX", "title": "Here’s What Makes Thermo Fisher Scientific (TMO) a Smart Investment Pick", "text": "", "author": "BioTechHealthX", "score": 1, "num_comments": 0, "date": "2026-03-21", "url": "https://reddit.com/r/BioTechHealthX/comments/1rzhfeu/heres_what_makes_thermo_fisher_scientific_tmo_a/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "reddit", "subreddit": "trading212", "title": "МYNZ already tied to Thermo Fisher, Quest, and Liquid for U.S. execution", "text": "For a microcap, Mainz Biomed is unusually well connected in the U.S.\n\n\n\nМYNZ has reported 100% sensitivity and about 95% specificity in its pancreatic feasibility study. But beyond the data, look at the infrastructure already in place.\n\n\n\nThermo Fisher Scientific, a major U.S. life sciences company listed under TMO, is collaborating with Mainz on its next generation colorectal test. Thermo brings assay platforms, automation, and manufacturing scale that can accelerate development and regulatory ", "author": "JellyTundraX", "score": 0, "num_comments": 1, "date": "2026-03-03", "url": "https://reddit.com/r/trading212/comments/1rjz1qy/мynz_already_tied_to_thermo_fisher_quest_and/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Pennystocksv2", "title": "MYNZ already plugged into Thermo Fisher, Quest and AI partners for U.S. scale", "text": "A lot of small biotechs talk about U.S. expansion. Fewer are already working with major U.S. infrastructure players.\n\n\n\nMainz Biomed, ticker MYNZ, is not building its U.S. strategy alone. Alongside reporting 100% sensitivity and about 95% specificity in its pancreatic feasibility study, the company has put real partnerships in place that support scaling and regulatory progress.\n\n\n\nStart with Thermo Fisher Scientific, a major U.S. life sciences company listed on NYSE under TMO. Mainz is collabora", "author": "Loose-Nature-2308", "score": 1, "num_comments": 0, "date": "2026-03-03", "url": "https://reddit.com/r/Pennystocksv2/comments/1rjyaj9/mynz_already_plugged_into_thermo_fisher_quest_and/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "investing", "title": "Just getting into investments - Started with Paper trading/Paper investing", "text": "As the title suggests, I have made some paper investments on investopedia simulator a couple months back and haven't seen any progress. Though the value fluctuates up and down, over the long run it has stayed around the same amount. I wanted to know what I was doing wrong, what i was doing right and what must I do to improve. \n\nI'm not committed to looking at charts everyday, though I try to keep myself updated with industry trends and how the market is generally looking like. \n\nI am attaching a", "author": "Ok_Tear5594", "score": 0, "num_comments": 12, "date": "2026-03-02", "url": "https://reddit.com/r/investing/comments/1rix96b/just_getting_into_investments_started_with_paper/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "investingforbeginners", "title": "Top Oversold/Overbought Stocks - March 17, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [GEGGL](https://marketrodeo.com/asset/GEGG", "author": "MarketRodeo", "score": 0, "num_comments": 4, "date": "2026-03-17", "url": "https://reddit.com/r/investingforbeginners/comments/1rw3mxr/top_oversoldoverbought_stocks_march_17_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "marketrodeo", "title": "Top Oversold/Overbought Stocks - March 17, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [GEGGL](https://marketrodeo.com/asset/GEGG", "author": "MarketRodeo", "score": 7, "num_comments": 2, "date": "2026-03-17", "url": "https://reddit.com/r/marketrodeo/comments/1rw3mw7/top_oversoldoverbought_stocks_march_17_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "marketrodeo", "title": "Top Oversold/Overbought Stocks - March 19, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [V](https://marketrodeo.com/asset/V) | Vis", "author": "MarketRodeo", "score": 10, "num_comments": 1, "date": "2026-03-19", "url": "https://reddit.com/r/marketrodeo/comments/1rxxm00/top_oversoldoverbought_stocks_march_19_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "marketrodeo", "title": "Top Oversold/Overbought Stocks - March 18, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [TMO](https://marketrodeo.com/asset/TMO) |", "author": "MarketRodeo", "score": 7, "num_comments": 1, "date": "2026-03-18", "url": "https://reddit.com/r/marketrodeo/comments/1rx110t/top_oversoldoverbought_stocks_march_18_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "marketrodeo", "title": "Top Oversold/Overbought Stocks - March 13, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [HD](https://marketrodeo.com/asset/HD) | T", "author": "MarketRodeo", "score": 10, "num_comments": 1, "date": "2026-03-13", "url": "https://reddit.com/r/marketrodeo/comments/1rski6o/top_oversoldoverbought_stocks_march_13_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "Top Oversold/Overbought Stocks - March 17, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [GEGGL](https://marketrodeo.com/asset/GEGG", "author": "MarketRodeo", "score": 1, "num_comments": 1, "date": "2026-03-17", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rw3mze/top_oversoldoverbought_stocks_march_17_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "investingforbeginners", "title": "Top Oversold/Overbought Stocks - March 13, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [HD](https://marketrodeo.com/asset/HD) | T", "author": "MarketRodeo", "score": 3, "num_comments": 1, "date": "2026-03-13", "url": "https://reddit.com/r/investingforbeginners/comments/1rski7t/top_oversoldoverbought_stocks_march_13_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "Top Oversold/Overbought Stocks - March 19, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [V](https://marketrodeo.com/asset/V) | Vis", "author": "MarketRodeo", "score": 2, "num_comments": 0, "date": "2026-03-19", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rxxm2x/top_oversoldoverbought_stocks_march_19_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "Top Oversold/Overbought Stocks - March 18, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [TMO](https://marketrodeo.com/asset/TMO) |", "author": "MarketRodeo", "score": 3, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rx1142/top_oversoldoverbought_stocks_march_18_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "Top Oversold/Overbought Stocks - March 13, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [HD](https://marketrodeo.com/asset/HD) | T", "author": "MarketRodeo", "score": 9, "num_comments": 0, "date": "2026-03-13", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rski99/top_oversoldoverbought_stocks_march_13_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "investingforbeginners", "title": "Top Oversold/Overbought Stocks - March 19, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [V](https://marketrodeo.com/asset/V) | Vis", "author": "MarketRodeo", "score": 1, "num_comments": 0, "date": "2026-03-19", "url": "https://reddit.com/r/investingforbeginners/comments/1rxxm1a/top_oversoldoverbought_stocks_march_19_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "investingforbeginners", "title": "Top Oversold/Overbought Stocks - March 18, 2026 📊", "text": "The Oversold/Overbought list shows stocks that are trading at extreme levels based on their Relative Strength Index (RSI), suggesting potential short-term reversals during the trading session.\n\n## 📉 **Oversold Stocks:**\n\nStocks with RSI below 30, potentially indicating oversold conditions and possible upward reversals.\n\n| Symbol | Company | RSI | Price | Change | %Change | Market Cap |\n|:-------|:--------|:---:|:-----:|:------:|:-------:|:----------:|\n| [TMO](https://marketrodeo.com/asset/TMO) |", "author": "MarketRodeo", "score": 0, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/investingforbeginners/comments/1rx112c/top_oversoldoverbought_stocks_march_18_2026/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "GreenWicks", "title": "Late-night stock scanning led me to this tiny cancer diagnostics company", "text": "Last weekend I was doing the usual - scrolling through small-cap stocks under $1, trying to see which ones actually have something real behind them. Not hype, not shells, but companies with real tech or real markets.\n\nThat’s how I ended up diving into MYNZ.\n\nAt first glance, it was just another ticker around $0.90, but the 52-week range from $0.55 to $5.62 immediately told me this stock can move. That’s always a signal that the market reacts when there’s news or data.\n\nThen I opened their invest", "author": "Carlene_Trammel", "score": 2, "num_comments": 1, "date": "2026-03-06", "url": "https://reddit.com/r/GreenWicks/comments/1rmetq8/latenight_stock_scanning_led_me_to_this_tiny/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "ChartNavigators", "title": "What plays are you looking into for tomorrow", "text": "[Sectors](https://www.sectorspdrs.com/)\n\n[Fed Calendar](https://www.federalreserve.gov/newsevents/calendar.htm)\n\n[Investing.com](https://www.investing.com/)\n\n\n\n\n\nUptrending Tickers\n\n\n\n\nRecommended Price Range: $120–$131\nArm Holdings plc (ARM) — 3/6/26 140.0C @ 1.22\nRecent Insights: Fundamental strength and technical momentum supporting trend continuation.\nAnalyst Consensus: Buy\nPrice Target: $132.9–$162.5\n\n\n\nRecommended Price Range: $116–$126\nMerck & Co., Inc. (MRK) — 3/6/26 127.0C @ 1.08\nRecent", "author": "Badboyardie", "score": 1, "num_comments": 1, "date": "2026-03-02", "url": "https://reddit.com/r/ChartNavigators/comments/1rif4xq/what_plays_are_you_looking_into_for_tomorrow/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "reddit", "subreddit": "ChartNavigators", "title": "What plays are you looking into for tomorrow", "text": "[Sectors](https://www.sectorspdrs.com/)\n\n[Fed Calendar](https://www.federalreserve.gov/newsevents/calendar.htm)\n\n[Investing.com](https://www.investing.com/)\n\n\n\n\n\nUptrending Tickers\n\n\n\n\nRecommended Price Range: $120–$131\nArm Holdings plc (ARM) — 3/6/26 140.0C @ 1.22\nRecent Insights: Fundamental strength and technical momentum supporting trend continuation.\nAnalyst Consensus: Buy\nPrice Target: $132.9–$162.5\n\n\n\nRecommended Price Range: $116–$126\nMerck & Co., Inc. (MRK) — 3/6/26 127.0C @ 1.08\nRecent", "author": "Badboyardie", "score": 1, "num_comments": 1, "date": "2026-02-27", "url": "https://reddit.com/r/ChartNavigators/comments/1rfsozh/what_plays_are_you_looking_into_for_tomorrow/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } } ] } }